Pfizer Inc. $PFE Position Decreased by Mattson Financial Services LLC

Key Points

• Mattson Financial Services LLC reduced its holdings in Pfizer Inc. by 30.6% during the second quarter, now owning 70,338 shares valued at approximately $1.7 million.
• Pfizer reported stronger-than-expected earnings with $0.78 EPS for the quarter, exceeding analysts' expectations, and a revenue of $14.65 billion.
• The company announced a quarterly dividend of $0.43 per share, representing an annualized yield of 7.1%, to be paid on December 1st.

Mattson Financial Services LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 30.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,338 shares of the biopharmaceutical company's stock after selling 31,055 shares during the period. Mattson Financial Services LLC's holdings in Pfizer were worth $1,705,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the 1st quarter valued at about $27,000. North Capital Inc. acquired a new position in shares of Pfizer in the first quarter worth about $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer in the first quarter worth about $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer in the second quarter worth about $29,000. Finally, Horizon Financial Services LLC acquired a new position in shares of Pfizer in the first quarter worth about $35,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

PFE stock opened at $24.22 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market cap of $137.70 billion, a P/E ratio of 12.88, a P/E/G ratio of 0.81 and a beta of 0.55. The firm has a 50 day simple moving average of $24.89 and a 200 day simple moving average of $24.12. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.53.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer's payout ratio is 91.49%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PFE. UBS Group reiterated a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley decreased their target price on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a report on Friday, October 10th. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.